Connect with us

Health

Pfizer’s 4 Focus Areas Will Produce 8 Blockbuster Cancer Drugs

Published

on

Pfizer
(Angus Liu/Fierce Pharma)

(CTN News) – Pfizer promised to have eight blockbuster cancer therapies by 2030 at a recent investor event for its expanded oncology division, but it did not disclose which ones.

According to Suneet Varma, commercial president of Pfizer Oncology, blockbusters will emerge from each of the division’s four therapeutic areas. In addition to breast surgery, genitourinary surgery, haematology surgery, and thoracic surgery are also included.

According to Varma, internal analysis suggested that, “on paper,” over eight cancer medicines may become blockbusters; however, the New York pharmaceutical company ultimately decided on just eight.

Pfizer made a significant wager on cancer last year when it paid $43 billion to acquire Seagen, a leader in antibody-drug conjugates. The large expense and the sharp decline in COVID sales are related to multiyear, multibillion dollar cost-cutting plans.

Similar to other Big Pharma mergers, the Seagen deal involved anticipated layoffs in Switzerland and the closure of a production plant in Washington.

“There’s nothing more to be done in oncology,” said Varma. Oncology will not be impacted by Pfizer’s most recentmulti-year cost cut. He declared that the company had finished containing costs and making organisational changes.

The Pfizer-Seagen merger is included in this list.

Pfizer designated Chris Boshoff, M.D., Ph.D., chief cancer officer and separated oncology in December.

As per Varma, Pfizer Oncology “thinks that it needs to be at the scale that it is at,” although it may expand its commercial infrastructure.

When lung cancer hits a “critical mass,”

Lung cancer, or thoracic cancer, is Pfizer’s least important focus area. Lung “will become its own franchise when it has that sufficient critical mass, which I think is upon us,” according to Varma’s assertion.

Pfizer has released updated phase 3 results for the next-generation ALK inhibitor Lorbrena in patients with recently diagnosed advanced non-small cell lung cancer that is positive for ALK. Compared to 8% of Xalkori patients, 60% of Lorbrena patients in the CROWN study survived without experiencing any further illness development after five years. Compared to Xalkori, Lorbrena lowered brain metastases by 94% and disease progression or death by 81%.

On May 31, analysts at Leerink Partners said that a phase 3 Xalkori head-to-head trial revealed that Alecensa, Roche’s current first-line standard of therapy, had a five-year overall survival rate of 62.5%. The results on progression-free survival were striking.

Ever after obtaining first-line clearance in March 2021, Lorbrena has not posed a threat to Alecensa’s ALK leadership. In 2023, Lorbrena sold $539 million to Pfizer, while Alecensa sold 1.5 billion Swiss francs to Roche. With the FDA’s April approval, Alecensa’s use was extended to postsurgical therapy for early-stage cancers.

Pfizer did not have data on this use.

Because of Lorbrena’s neurotoxicity, which can cause seizures, mood or cognitive problems, and mental status, more physicians are not using it as a first-line medication.

Though some physicians and patients may be convinced to use Lorbrena right away by its best-in-class tumour progression results, Leerink analysts cautioned that “we do not expect it to rapidly become standard of care given the toxicity and tolerability profile, especially with no approved drugs to treat patients failing [Lorbrena].” Pfizer is “very bullish” on Lorbrena, according to Varma.

Yes, additional therapeutic management is required, according to Varma. “But because patients live longer, it’s worth it.” “The results are not as good when we look at the data of people who switched [to Lorbrena],” Varma continued. “With Lorbrena, we think your first chance is your best chance.”

According to Varma, Pfizer is using its knowledge in managing Seagen therapy to support Lobrena. Because of the complicated side effects of ADCs, Seagen’s advice might be helpful.

Genitourinary cancer will be surpassed by

Pfizer’s cancer portfolio has been dominated by tiny pharmaceuticals; nevertheless, Seagen and its ADC portfolio enable Pfizer to improve its biologics commercial capabilities.

Varma claimed that the cross-boosting is reciprocal. Pfizer uses extensive and complex marketing. Prior to the merger, Pfizer Oncology’s commercial and medical sales staff was double that of Seagen. The massive pharmaceutical business is now utilising its digital and public relations capabilities for all Seagen medications.

In terms of investment and resources, sales force prioritisation, and agency support, Varma claimed that Pfizer Oncology is providing “disproportionate attention” to the legacy Seagen bladder cancer medication Padcev, which is partnered with Astellas and ranked in the top 10 brands.

SEE ALSO:

Past COVID Infections May Help Prevent Colds. Would It Make Vaccines Better?

Continue Reading

Health

Report Causes Pfizer Stock to Climb Approximately $1 Billion Acquired by Starboard

Published

on

By

Pfizer

(VOR News) – According to a rumor that activist investor Pfizer Starboard Value has taken a holding in the struggling pharmaceutical business that is expected to be worth around one billion dollars, the stock of Pfizer (PFE) is on the increase in premarket trading on Monday.

This comes after the report was made public. The report was made available to the general public following this. Starboard Value was successful in moving forward with the acquisition of the position.

Starboard is said to have approached Ian Read, a former chief executive officer of Pfizer, and Frank D’Amelio, a former chief financial officer, in order to seek assistance with its goals of boosting the performance of the company, according to the Wall Street Journal. Read and D’Amelio are both former Pfizer executives.

The purpose of this is to facilitate the accomplishment of its objectives, which include enhancing the overall performance of the firm.

In their previous jobs, D’Amelio and Read were chief financial officers.

It is stated in the report that the hedge fund is of the opinion that Pfizer, which is currently being managed by Albert Bourla, who succeeded Read as Chief Executive Officer (CEO) in 2019, does not demonstrate the same level of mergers and acquisitions (M&A) discipline that Read did. Bourla took over for Read in 2019. Read was succeeded by Bourla in the year 2019.

Pfizer, a multinational pharmaceutical conglomerate, has made substantial investments in the acquisition of more companies that are involved in the research and development of cancer medicines.

These businesses have been acquired for billions of dollars. The biotechnology company Seagen, which was acquired by Pfizer in the previous year for a price of $43 billion, is included in this category. One of the businesses that can be classified as belonging to this category is Seagen.

In spite of the fact that the S&P 500 Index experienced a 21% increase in 2024.

No major trading occurred in Pfizer stock that year.

Due to the fact that the demand for Pfizer’s COVID-19 vaccines fell after the firm reached its pandemic peak in 2021, the share price of the corporation has decreased by over fifty percent since that time.

This drop has occurred ever since the company’s shares reached their maximum peak, which was during the time that this decline occurred. Not only have they not changed at all, but they have also remained essentially stable. This is in contrast to the S&P 500, which has gained 21% since the beginning of this year.

Recently, the corporation was forced to take a hit when it decided to recall all of the sickle cell illness medications that it had distributed all over the world.

Fears that the prescription could lead patients to experience severe agony and possibly even death were the impetus for the decision to recall the product. In spite of the fact that Pfizer’s stock is increasing by almost three percent as a result of the news that followed the company’s decision, this is the circumstance that has come about.

SOURCE: IPN

SEE ALSO:

New Study Reveals Drinking Soda Pop Increases the Risk of Stroke

The Mpox Vaccine’s Protection Decreases Within a Year; Booster Requirements

 

Continue Reading

Health

New Study Reveals Drinking Soda Pop Increases the Risk of Stroke

Published

on

By

Soda Pop Increases the Risk of Stroke
If you drink too much soda, fruit juice and coffee, beware!

A recent report from global research indicates that excessive consumption of coffee or soda pop is associated with an increased risk of stroke, although the intake of black and green tea is correlated with a reduced risk. Excessive consumption of soda pop or coffee warrants caution!

Recent research indicates that it may substantially elevate the risk of stroke.

Consuming four cups of coffee daily elevates the risk of stroke, according to studies, although ingesting 3-4 cups of black or green tea daily typically offers protection against stroke. Additionally, consume more coffee; it may reduce your risk of mortality.

Recent findings from global research studies co-led by the University of Galway and McMaster University, alongside an international consortium of stroke researchers, indicate that soda, encompassing both sugar-sweetened and artificially sweetened variants such as diet or zero sugar, is associated with a 22 percent heightened risk of stroke. The risk escalated significantly with the consumption of two or more of these beverages daily.

Stroke Risk Fizzy Drinks and Soda Pop

The correlation between fizzy drinks consumption and stroke risk was most pronounced in Europe, the Middle East, Africa, and South America. Women exhibit the most elevated risk of stroke from bleeding (intracranial hemorrhage) associated with fruit juice beverages. Consuming over 7 cups of water daily diminishes the likelihood of stroke due to a clot.

Researchers observed that numerous items advertised as fruit juice are derived from concentrates and have added sugars and preservatives, potentially negating the advantages often associated with fresh fruit and instead elevating stroke risk.

Fruit juice beverages were associated with a 37 percent heightened risk of stroke resulting from bleeding (intracranial hemorrhage). Consuming two of these beverages daily increases the risk thrice.

Consuming over four cups of coffee daily elevates the risk of stroke by 37 percent, although lower consumption levels do not correlate with stroke risk. Conversely, tea consumption was associated with an 18-20 percent reduction in stroke risk. Additionally, consuming 3-4 cups daily of black tea, such as Breakfast and Earl Grey varieties, excluding green and herbal teas, was associated with a 29 percent reduced risk of stroke.

Consuming 3-4 cups of green tea daily was associated with a 27 percent reduction in stroke risk. Notably, the addition of milk may diminish or inhibit the advantageous effects of antioxidants present in tea. The lower risk of stroke associated with tea consumption was negated for individuals who added milk.

Disclaimer: This article is intended solely for informational reasons and should not be considered a replacement for professional medical counsel. Consistently consult your physician regarding any inquiries pertaining to a medical problem.

Related News:

Starbucks Faces Sales Decline Amid Price Fatigue and Rising Competition

Starbucks Faces Sales Decline Amid Price Fatigue and Rising Competition

Continue Reading

Health

Following a Diagnosis of Breast Cancer, What Else Should You Know?

Published

on

By

Breast Cancer

(VOR News) – Even though breast cancer affects one in eight American women, receiving a diagnosis can make a woman feel isolated.

Experts in breast cancer from the American College of Physicians (ACS) advise patients on how to manage their disease so that they may better cope with this awful information.

First, the kind and stage of breast cancer dictates the course of your care.

In addition to immunotherapy and chemotherapy, there are various surgical options available for the treatment of breast cancer.

Women of African descent are disproportionately affected by triple-negative breast cancer, an extremely aggressive form of the disease that has never proven easy to treat.

According to the American Cancer Society, pembrolizumab (Keytruda), an immunotherapy, has been shown to be helpful when combined with chemotherapy and is currently the recommended course of treatment for certain combinations of triple-negative breast cancer.

In her presentation, Dr. Katharine Yao said, “It’s really important that the patient and physician discuss the patient’s preferences and values when deciding what type of treatment to pursue and that they have an honest, individualized discussion with their care team.”

She is currently responsible for developing breast cancer treatment recommendations for more than 575 hospitals and institutions nationwide in her role as chair of the American College of Surgeons’ National Accreditation Program for Breast Institutions (NAPBC).

Yao, vice chair of research at Endeavor Health NorthShore Hospitals in New York, pointed out that each decision made about a patient’s treatment plan should take her preferences and diagnosis into consideration.

She ought to think about whether she would prefer a mastectomy—a surgical procedure that involves removing the entire breast with or without reconstruction—or a lumpectomy, which involves a surgical procedure that spares part of the breast tissue.

She stated that “the breast cancer you have may be very different from the breast cancer you hear about in your neighbor, colleague, or friend” in a press release issued by the American Cancer Society (ACS).

“Consider that while discussing breast cancer with others.”

Throughout your journey, it is critical that you look after your emotional health because having breast cancer may have a detrimental impact on your mental health.

“Getting a cancer diagnosis does not mean that everything in your life stops to be normal.” Director of the Fellowship in the Diseases of the Breast program at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas and state head of the American Cancer Society Commission on Cancer for Arkansas, Dr. Daniela Ochoa She thinks adding the burden of a cancer diagnosis and treatment to all the other pressures in life may be taxing.

“Managing stress and emotional health is vital component of a treatment plan.”

Ochoa recommends clinically trained psychologists and social workers who have assisted people in coping with cancer to anyone receiving treatment. Learning coping techniques might also be facilitated by joining cancer support groups or cancer wellness initiatives.

Breast cancer specialists say your care team is crucial.

The American Cancer Society (ACS) defines comprehensive care as having support at every stage of the procedure from surgeons, oncologists, patient navigators, nurses, social workers, psychologists, and other specialists.

After receiving a breast cancer diagnosis, women should see a surgeon or medical oncologist to explore their options; nevertheless, treatment shouldn’t be discontinued after just one appointment or after surgery is over.

Additionally, you can ask trustworthy friends or family members to accompany you to appointments and aid you with research or notes. They could serve as a network of support for you.

Yao stated in his talk that “one of the most important things is that patients should search out a team they have confidence in, that they trust will have their back when they need it, and a team they feel they can get access to and that will help them when they are in need.”

SOURCE: MP

SEE ALSO:

The Mpox Vaccine’s Protection Decreases Within a Year; Booster Requirements

COVID was a Paradigm Shift in Health Policymaking, Says Commissioner Stella Kyriakides.

Rwanda Reports 8 Deaths Linked To Ebola-Like Marburg Virus Days After It Declared An Outbreak

 

Continue Reading

Trending